Johnson & Johnson logo

Johnson & Johnson(JNJ)

Today's top pick Today’s top pick
upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
5-STAR RATING
STRONG BUY
BUY for 5 days
PROFIT SINCE LAST BUY
+1.29% ▲
LAST CLOSE
$285.75
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for JNJ

11/13/2026: JNJ (5-star) is a STRONG-BUY. BUY for 5 days. Simulated Profits (1.29%). Updated daily EoD!

Johnson & Johnson is a premier global healthcare enterprise operating through innovative medicine and medtech segments. The company's core strengths lie in its blockbuster pharmaceutical portfolio, strong research capabilities, and elite balance sheet supporting consistent dividend growth. Its primary growth opportunity stems from pipeline expansion in oncology and strategic acquisitions in medical technology. Key risks include impending patent expirations, pricing pressures, and litigation uncertainties. The stock suits conservative and income-focused investors seeking defensive stability, with ongoing attention required on pipeline execution and patent cliff offsets.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitJ&J offers steady mid-single-digit growth rather than high-octane hyper-growth.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on a positive Upturn signal driven by strong pipeline or medtech execution.
Value investorStrong fitThe stock often trades at reasonable valuation multiples relative to its stable healthcare earnings and cash flows.
Dividend investorStrong fitAs a Dividend King with decades of consecutive payout increases, it is a premier option for income-seeking investors.
Low-risk investorStrong fitIts defensive business model, low economic sensitivity, and AAA-rated financial profile suit conservative portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityLowHealthcare demand is defensive, resulting in lower price volatility compared to cyclical sectors.
Valuation riskMediumValuation remains reasonable, but broad market shifts can influence healthcare sector pricing multiples.
Competition risk (Pharmaceutical and MedTech competition)Medium / highIntense rivalry from peers in oncology, immunology, and medical devices threatens market share and pricing.
Business qualityStrongThe company boasts elite franchise quality, high margins, and world-class operational scale.
Dividend incomeStrongReliable cash flow generation secures its elite dividend growth record.
Execution riskMediumSuccessful clinical trials and smooth integration of large MedTech acquisitions are vital to sustain growth.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 687.89B USD
Price to earnings Ratio 43.36
1Y Target Price 279.41
Price to earnings Ratio 43.36
1Y Target Price 279.41
Volume (30-day avg) 7.7M shares
Beta 0.2
52 Weeks Range 191.58 - 288.11
Updated Date 11/15/2026
52 Weeks Range 191.58 - 288.11
Updated Date 11/15/2026
Dividends yield (FY) 1.86%
Basic EPS (TTM) 6.59

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - General

BUY participation
77.8%
Active BUY / eligible
7 / 9
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit 63%
Avg. Invested days 64
Today’s Advisory Strong Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
JNJ receives a 4-star rating, supported by strong unit economics, solid company fundamentals, solid quantitative characteristics, and solid analyst coverage. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
JNJ has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+90.6%) and strong cash generation (FCF margin 20.9%) are partially offset by moderate revenue growth (+6.0%), very low insider ownership of 0.22%.

Financial Health Rating

★★★★★
JNJ's financial health is supported by strong cash strength, including free-cash-flow generation of $19.7B (20.9% of revenue). Liquidity is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is JNJ's strongest growth driver at +90.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+6.0%, moderate) and free-cash-flow growth (-0.7%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 77.1% and approximately 99.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.22%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 8.81%
Vanguard Capital Management, LLC 6.53%
State Street Corp 5.56%
Vanguard Portfolio Management, LLC 2.67%
Geode Capital Management, LLC 2.45%

Unit Economics (Per $1K Revenue)

★★★★★
JNJ generates approximately $679 of gross profit, $272 of operating income, and $209 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins and solid cash conversion support the rating, although capital efficiency remains solid.

Economic Dimensions

★★★★★
Effective Tax Rate: 17.73%

Quantitative Style Profile

★★★★★
JNJ has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Quality TiltLow VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Innovative Medicine (Pharmaceuticals)Prescription drugs and biologics targeting oncology, immunology, neuroscience, and cardiovascular diseases.This is J&J's primary profit engine, driven by blockbuster patented therapies.
MedTechSurgical instruments, orthopedics, vision care, and cardiovascular intervention devices.Provides steady, recurring hospital-based revenue tied to surgical procedures globally.
Geographic ExposureGlobal commercial sales spanning North America, Europe, Asia-Pacific, and Latin America.International diversification cushions against regional economic downturns.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE 43.36
Forward PE 24.1
Enterprise Value 715.31B
Price to Sales(TTM) 6.92
Enterprise Value 715.31B
Price to Sales(TTM) 6.92
Enterprise Value to Revenue 7.2
Enterprise Value to EBITDA 26.68
Shares Outstanding 2.41B
Shares Floating 2.40B
Shares Outstanding 2.41B
Shares Floating 2.40B
Percent Insiders 0.22
Percent Institutions 77.06

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.